Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7299663 | 0.81 | NPY5R (0.46) | NPY5RNOTUMMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL803705 | 0.77 | F10 (0.43) | NPY5RCYP3A4 | |
| SCHEMBL7293116 | 0.77 | MAPT (0.54) | MAPTSMN1; SMN2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL4171137 | 0.77 | NOTUM (0.48) | NPY5RNOTUMMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL4169504 | 0.74 | NPY5R (0.53) | NPY5RNOTUMMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL2636420 | 0.73 | NOTUM (0.44) | NPY5RNOTUM | |
| SCHEMBL19652188 | 0.73 | NOTUM (0.52) | NPY5RNOTUMMAPTCYP3A4 | |
| SCHEMBL14336729 | 0.72 | NPY5R (1.00) | NPY5R | |
| SCHEMBL4171141 | 0.72 | CKS1B (0.48) | NOTUMMAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL2636418 | 0.72 | MCHR1 (0.47) | NOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124663-A1 | Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1896415-A1 | NOVEL N-PHENYL-PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006131524-A1 | NOVEL N-PHENYL-PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124663-A1 | Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | NPY5R 186/4885NOTUM 640/4885MAPT 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.